Stock of the Day

Larimar Therapeutics (LRMR)

$2.73

+$0.27 (+10.8%)

Market Cap: $174.86M

About Larimar Therapeutics

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.